Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Swedish Orphan Biovitrum AB (Sobi) SWOBY BIOVF and Apellis Pharmaceuticals, Inc. APLS on Thursday released topline data results from Phase 3 VALIANT study of systemic pegcetacoplan for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative …